Table 1 Clinicopathological features of included patients, n (%).
Characteristics | Description |
|---|---|
Age, years, (\(\stackrel{-}{x}\)±s) | 63.8 ± 12.5 |
Lymphovascular invasion | |
Absent/focal | 30 (69.8) |
Prominent | 13 (30.2) |
Tumor grade | |
I–II | 37 (86.0) |
III | 6 (14.0) |
Tumor T stage | |
T1 | 19 (44.2) |
T2 | 23 (53.5) |
T3 | 1 (2.3) |
Tumor N stage | |
N0 | 23 (53.5) |
N1 | 12 (27.9) |
N2 | 6 (14.0) |
N3 | 2 (4.7) |
Ki-67 expression | |
< 15% | 5 (11.6) |
15–30% | 23 (53.5) |
> 30% | 15 (34.9) |
Estrogen receptor/progesterone receptor status | |
Positive | 42 (97.7) |
Negative | 1 (2.3) |
Human epidermal growth factor receptor 2 status | |
Positive | 5 (11.6) |
Negative | 38 (88.4) |
Adjuvant endocrine therapy | |
Yes | 29 (67.4) |
No | 14 (32.6) |
Adjuvant chemotherapy | |
Yes | 21 (48.8) |
No | 22 (51.2) |
Adjuvant radiotherapy | |
Yes | 13 (30.2) |
No | 30 (69.8) |
Recurrence index for local recurrence | |
Low-risk | 26 (60.5) |
High-risk | 17 (39.5) |
Recurrence index for distant recurrence | |
Low-risk | 17 (39.5) |
High-risk | 26 (60.5) |
